Sally A. Baylis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sally A. Baylis has a total of 181 co-authors. Here are the top co-authors by number of shared publications:
Johannes Blümel
Division Virology Paul‐Ehrlich‐Institut Langen Germany
13 shared publications- Constanze Yue
Paul-Ehrlich-Institut, Department of Virology, 63225 Langen, Germany
4 shared publications - Victor Max Corman
Institute of Virology, Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humbolt-Universität zu Berlin
4 shared publications J. Blümel
Division of Virology, Paul-Ehrlich-Institut, Langen, Germany
3 shared publications- Lia Laura Lewis-Ximenez
Instituto Oswaldo Cruz, Fundação Oswaldo Cruz, Rio de Janeiro, Brazil
3 shared publications - Ana Avellón
CIBER Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain
2 shared publications
Latest Publications
- Open Access
- 17 August 2026
- Published by Elsevier in The Lancet Microbe
- Vol. 7 (11)
A WHO International Standard for neutralising antibodies to Chikungunya virus: development and evaluation
- 17 August 2026
- Published by Elsevier in The Lancet Microbe
- Vol. 7 (11)
Open AccessA WHO International Standard for neutralising antibodies to Chikungunya virus: development and evaluation
- Open Access
- 12 June 2026
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 13, 1855687
Commentary: A comprehensive review of diagnostic approaches for hepatitis D
We read with interest the review by Liu et al (1) on diagnostic testing for hepatitis delta virus (HDV). Given the burden of disease, the authors highlight the urgent need to establish standardized protocols and international standards for the detection of HDV to ensure appropriate management and timely treatment of hepatitis delta infections. The World Health Organization (WHO) has recently prioritized the inclusion of HDV in the WHO Model List of Essential In Vitro Diagnostics including serology, rapid tests as well as nucleic acid amplification technique assays (NAT or NAAT) (2). Liu et al. (1) refer to the 1 st WHO International Standard (IS) for HDV RNA for NAT-based assays (code number 7657/12); however, the authors incorrectly state that the 1 st WHO IS is no longer available.The 1 st WHO IS was prepared using viremic plasma from a Turkish patient infected with genotype 1 HDV. Similar to other WHO ISs for NAT, the choice of strain used to prepare the standard was based upon global prevalence (3). The 1 st WHO IS was established by the WHO Expert Committee on Biological Standardization (ECBS) in October 2013 (4). The international study to evaluate the IS demonstrated that reporting of viral loads varied by up to 1,000-fold; however, when results were expressed against the WHO IS, there was a marked improvement in the agreement between laboratories. It is important to clarify that this standard remains available and is currently distributed by the Paul-Ehrlich-Institut (PEI) in Langen, Germany.
- 12 June 2026
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 13, 1855687
Open AccessCommentary: A comprehensive review of diagnostic approaches for hepatitis D
We read with interest the review by Liu et al (1) on diagnostic testing for hepatitis delta virus (HDV). Given the burden of disease, the authors highlight the urgent need to establish standardized protocols and international standards for the detection of HDV to ensure appropriate management and timely treatment of hepatitis delta infections. The World Health Organization (WHO) has recently prioritized the inclusion of HDV in the WHO Model List of Essential In Vitro Diagnostics including serology, rapid tests as well as nucleic acid amplification technique assays (NAT or NAAT) (2). Liu et al. (1) refer to the 1 st WHO International Standard (IS) for HDV RNA for NAT-based assays (code number 7657/12); however, the authors incorrectly state that the 1 st WHO IS is no longer available.The 1 st WHO IS was prepared using viremic plasma from a Turkish patient infected with genotype 1 HDV. Similar to other WHO ISs for NAT, the choice of strain used to prepare the standard was based upon global prevalence (3). The 1 st WHO IS was established by the WHO Expert Committee on Biological Standardization (ECBS) in October 2013 (4). The international study to evaluate the IS demonstrated that reporting of viral loads varied by up to 1,000-fold; however, when results were expressed against the WHO IS, there was a marked improvement in the agreement between laboratories. It is important to clarify that this standard remains available and is currently distributed by the Paul-Ehrlich-Institut (PEI) in Langen, Germany.
- Open Access
- 15 May 2024
- Published by Elsevier in The Lancet Microbe
- Vol. 5 (9) , 100874
Harmonising the measurement of neutralising antibodies against chikungunya virus: a path forward for licensing of new vaccines?
- 15 May 2024
- Published by Elsevier in The Lancet Microbe
- Vol. 5 (9) , 100874
Open AccessHarmonising the measurement of neutralising antibodies against chikungunya virus: a path forward for licensing of new vaccines?
- 21 February 2024
- Published by Wiley in Transfusion
- Vol. 64 (2) , 416-418
In Response: Getting the measure of hepatitis A virus (HAV): A better understanding of the RNA content of HAV reference material and blood donations
- 21 February 2024
- Published by Wiley in Transfusion
- Vol. 64 (2) , 416-418
In Response: Getting the measure of hepatitis A virus (HAV): A better understanding of the RNA content of HAV reference material and blood donations
- 26 April 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (3) , 870-872
Identification of rabbit hepatitis E virus (HEV) and novel HEV clade in Irish blood donors
- 26 April 2022
- Published by Elsevier in Journal of Hepatology
- Vol. 77 (3) , 870-872
Identification of rabbit hepatitis E virus (HEV) and novel HEV clade in Irish blood donors
- Open Access
- 30 December 2021
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 68 (1) , 181-191
An Evaluation of Hepatitis E Virus Molecular Typing Methods
Hepatitis E virus (HEV) is a major cause of acute viral hepatitis. Better understanding of HEV subtypes involved in hepatitis E infections is essential. Investigation of sources and routes of transmission and the identification of potential clusters/outbreaks rely upon molecular typing of viral strains. A study was carried out to evaluate the ability of laboratories to undertake molecular typing with genotype and subtype determination. A blinded panel of 11 different Orthohepevirus A strains was distributed to 28 laboratories performing HEV sequence analysis. Laboratories used their routine HEV sequencing and genotyping methods. Results were returned by 25 laboratories. Overall, 93% samples were assigned to the correct genotype and 81% were assigned to the correct subtype. Fragments amplified for typing ranged in size and the sequencing assays targeted both the structural and non-structural protein-coding regions. There was good agreement between the reported sequences where methods targeted overlapping fragments. In some cases, incorrect genotypes/subtypes were reported, including those not contained in the panel, and in one case, a genotype was reported for a blinded control sample containing Zika virus; collectively these data indicate contamination problems. In general, identification of genotypes was good; however, in a small number of cases, there was a failure to generate sequences from some of the samples. There was generally broad agreement between the use of online typing tools such as the one provided by HEVnet and curated lists of published HEV reference sequences; however, going forward harmonization between these resources is essential.
- 30 December 2021
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 68 (1) , 181-191
Open AccessAn Evaluation of Hepatitis E Virus Molecular Typing Methods
Hepatitis E virus (HEV) is a major cause of acute viral hepatitis. Better understanding of HEV subtypes involved in hepatitis E infections is essential. Investigation of sources and routes of transmission and the identification of potential clusters/outbreaks rely upon molecular typing of viral strains. A study was carried out to evaluate the ability of laboratories to undertake molecular typing with genotype and subtype determination. A blinded panel of 11 different Orthohepevirus A strains was distributed to 28 laboratories performing HEV sequence analysis. Laboratories used their routine HEV sequencing and genotyping methods. Results were returned by 25 laboratories. Overall, 93% samples were assigned to the correct genotype and 81% were assigned to the correct subtype. Fragments amplified for typing ranged in size and the sequencing assays targeted both the structural and non-structural protein-coding regions. There was good agreement between the reported sequences where methods targeted overlapping fragments. In some cases, incorrect genotypes/subtypes were reported, including those not contained in the panel, and in one case, a genotype was reported for a blinded control sample containing Zika virus; collectively these data indicate contamination problems. In general, identification of genotypes was good; however, in a small number of cases, there was a failure to generate sequences from some of the samples. There was generally broad agreement between the use of online typing tools such as the one provided by HEVnet and curated lists of published HEV reference sequences; however, going forward harmonization between these resources is essential.
- Open Access
- 28 October 2021
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 10 (43) , e0074021
Genome Sequences of West Nile Virus Reference Materials
We report the sequences of two West Nile virus (WNV) strains (lineages 1 and 2) developed by the Paul-Ehrlich-Institut as reference materials. The materials are calibrated against the 1st World Health Organization WNV RNA International Standard and are intended for use in nucleic acid technology assays supporting transfusion safety.
- 28 October 2021
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 10 (43) , e0074021
Open AccessGenome Sequences of West Nile Virus Reference Materials
We report the sequences of two West Nile virus (WNV) strains (lineages 1 and 2) developed by the Paul-Ehrlich-Institut as reference materials. The materials are calibrated against the 1st World Health Organization WNV RNA International Standard and are intended for use in nucleic acid technology assays supporting transfusion safety.
- Open Access
- 23 June 2020
- Published by MDPI AG in Proceedings
- Vol. 50 (1) , 95
Analysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated with a Candidate CHIKV Vaccine
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes severe flu-like symptoms. The acute symptoms disappear after one week, but chronic arthralgia can persist for years. Here, humoral immune responses in CHIKV-infected patients and vaccinees were analyzed. Alphavirus neutralization activity was analyzed with pseudotyped lentiviral vectors and antibody epitope mapping was performed with a peptide array. The greatest CHIKV neutralization activity was observed 60–92 days after onset of symptoms. The amount of CHIKV-specific antibodies, their binding avidity, and cross-reactivity with other alphaviruses increased over time. CHIKV and o’nyong-nyong virus (ONNV) were both neutralized to a similar extent. Linear antibody binding epitopes were mainly found in E2 domain B and the acid-sensitive regions (ASRs). In addition, serum samples from healthy volunteers vaccinated with a measles-vectored Chikungunya vaccine candidate, MV-CHIK, were analyzed. Neutralization activity in the samples from the vaccine cohort was lower than in samples from CHIKV-infected patients. In contrast to infection, vaccination induced cross-neutralization with ONNV and the E2 ASR1 was the major antibody target. These data could assist vaccine design and enable the identification of correlates of protection necessary for vaccine efficacy.
- 23 June 2020
- Published by MDPI AG in Proceedings
- Vol. 50 (1) , 95
Open AccessAnalysis of Humoral Immune Responses in Chikungunya Virus (CHIKV)-Infected Patients and Individuals Vaccinated with a Candidate CHIKV Vaccine
Chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus that causes severe flu-like symptoms. The acute symptoms disappear after one week, but chronic arthralgia can persist for years. Here, humoral immune responses in CHIKV-infected patients and vaccinees were analyzed. Alphavirus neutralization activity was analyzed with pseudotyped lentiviral vectors and antibody epitope mapping was performed with a peptide array. The greatest CHIKV neutralization activity was observed 60–92 days after onset of symptoms. The amount of CHIKV-specific antibodies, their binding avidity, and cross-reactivity with other alphaviruses increased over time. CHIKV and o’nyong-nyong virus (ONNV) were both neutralized to a similar extent. Linear antibody binding epitopes were mainly found in E2 domain B and the acid-sensitive regions (ASRs). In addition, serum samples from healthy volunteers vaccinated with a measles-vectored Chikungunya vaccine candidate, MV-CHIK, were analyzed. Neutralization activity in the samples from the vaccine cohort was lower than in samples from CHIKV-infected patients. In contrast to infection, vaccination induced cross-neutralization with ONNV and the E2 ASR1 was the major antibody target. These data could assist vaccine design and enable the identification of correlates of protection necessary for vaccine efficacy.
- Open Access
- 18 April 2020
- Published by Springer Nature in Virus Genes
- Vol. 56 (4) , 522-526
Identification of a novel bovine copiparvovirus in pooled fetal bovine serum
A novel parvovirus was identified as a cell culture contaminant by metagenomic analysis. Droplet digital PCR (ddPCR) was used to determine viral loads in the cell culture supernatant and further analysis, by ddPCR and DNA sequencing, demonstrated that fetal bovine serum (FBS) used during cell culture was the source of the parvovirus contamination. The FBS contained ~ 50,000 copies of the novel parvovirus DNA per ml of serum. The viral DNA was resistant to DNAse digestion. Near-full length sequence of the novel parvovirus was determined. Phylogenetic analysis demonstrated that virus belongs to theCopiparvovirusgenus, being most closely related to bovine parvovirus 2 (BPV2) with 41% identity with the non-structural protein NS1 and 47% identity with the virus capsid protein of BPV2. A screen of individual and pooled bovine sera identified a closely related variant of the novel virus in a second serum pool. For classification purposes, the novel virus has been designated bovine copiparvovirus species 3 isolate JB9 (bocopivirus 3-JB9).
- 18 April 2020
- Published by Springer Nature in Virus Genes
- Vol. 56 (4) , 522-526
Open AccessIdentification of a novel bovine copiparvovirus in pooled fetal bovine serum
A novel parvovirus was identified as a cell culture contaminant by metagenomic analysis. Droplet digital PCR (ddPCR) was used to determine viral loads in the cell culture supernatant and further analysis, by ddPCR and DNA sequencing, demonstrated that fetal bovine serum (FBS) used during cell culture was the source of the parvovirus contamination. The FBS contained ~ 50,000 copies of the novel parvovirus DNA per ml of serum. The viral DNA was resistant to DNAse digestion. Near-full length sequence of the novel parvovirus was determined. Phylogenetic analysis demonstrated that virus belongs to theCopiparvovirusgenus, being most closely related to bovine parvovirus 2 (BPV2) with 41% identity with the non-structural protein NS1 and 47% identity with the virus capsid protein of BPV2. A screen of individual and pooled bovine sera identified a closely related variant of the novel virus in a second serum pool. For classification purposes, the novel virus has been designated bovine copiparvovirus species 3 isolate JB9 (bocopivirus 3-JB9).
- Open Access
- 1 November 2019
- Published by Elsevier in Journal of Clinical Virology
- Vol. 120, 63-67
Standardising surveillance of hepatitis E virus infection in the EU/EEA: A review of national practices and suggestions for the way forward
- 1 November 2019
- Published by Elsevier in Journal of Clinical Virology
- Vol. 120, 63-67
Open AccessStandardising surveillance of hepatitis E virus infection in the EU/EEA: A review of national practices and suggestions for the way forward